Last reviewed · How we verify
celecoxib and ibuprofen SR — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
celecoxib and ibuprofen SR (celecoxib and ibuprofen SR) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| celecoxib and ibuprofen SR TARGET | celecoxib and ibuprofen SR | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- celecoxib and ibuprofen SR CI watch — RSS
- celecoxib and ibuprofen SR CI watch — Atom
- celecoxib and ibuprofen SR CI watch — JSON
- celecoxib and ibuprofen SR alone — RSS
Cite this brief
Drug Landscape (2026). celecoxib and ibuprofen SR — Competitive Intelligence Brief. https://druglandscape.com/ci/celecoxib-and-ibuprofen-sr. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab